Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness

• Published in: Cancer cell international Vol. 21; no. 1; pp. 1 - 507
• Main Authors: Bonfil, R. Daniel, Chen, Wei, Vranic, Semir, Sohail, Anjum, Shi, Dongping, Jang, Hyejeong, Kim, Hyeong-Reh, Prunotto, Marco, Fridman, Rafael
• Format: Journal Article
• Language: English
• Published: London BioMed Central 21-09-2021; BMC
• Subjects: Antigens; Binding sites; Cancer therapies; Collagen; Cytoplasm; DDR1; Epithelial cells; Immunohistochemistry; Kinases; Laboratories; Ligands; Localization; Medical prognosis; Metastasis; Monoclonal antibodies; Mortality; Phosphorylation; Primary Research; Prognostic markers; Prostate cancer; Protein-tyrosine kinase receptors; Receptor tyrosine kinases; Tumors
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-021-02206-1

Background The Discoidin Domain Receptor 1 (DDR1) is one of the two members of a unique family of receptor tyrosine kinase receptors that signal in response to collagen, which has been implicated in cancer progression. Here, we examined the expression of DDR1 in prostate cancer (PCa), and assessed its potential value as a prognostic marker, as a function of grade, stage and other clinicopathologic parameters. Methods We investigated the association between the expression level and subcellular localization of DDR1 protein and PCa aggressiveness by immunohistochemistry, using tissue microarrays (TMAs) encompassing 200 cases of PCa with various Gleason scores (GS) and pathologic stages with matched normal tissue, and a highly specific monoclonal antibody. Results DDR1 was found to be localized in the membrane, cytoplasm, and nuclear compartments of both normal and cancerous prostate epithelial cells. Analyses of DDR1 expression in low GS (≤ 7[3 + 4]) vs high GS (≥ 7[4 + 3]) tissues showed no differences in nuclear or cytoplasmic DDR1in either cancerous or adjacent normal tissue cores. However, relative to normal-matched tissue, the percentage of cases with higher membranous DDR1 expression was significantly lower in high vs. low GS cancers. Although nuclear localization of DDR1 was consistently detected in our tissue samples and also in cultured human PCa and normal prostate-derived cell lines, its presence in that site could not be associated with disease aggressiveness. No associations between DDR1 expression and overall survival or biochemical recurrence were found in this cohort of patients. Conclusion The data obtained through multivariate logistic regression model analysis suggest that the level of membranous DDR1 expression status may represent a potential biomarker of utility for better determination of PCa aggressiveness.